New Two-Drug combo aims to beat back returning myeloma
NCT ID NCT07463807
First seen Mar 21, 2026 · Last updated Jun 19, 2026 · Updated 11 times
Summary
This study compares a new combination of teclistamab and pomalidomide against the standard three-drug regimen (carfilzomib, pomalidomide, dexamethasone) for multiple myeloma that has come back after initial treatment. About 162 participants will receive either the new or standard therapy. The goal is to see if the new combo is safe and can reduce cancer cells to undetectable levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teclistamab and pomalidomide
What this could lead to
If it works, this combination could offer a more effective, fixed-duration treatment option for people with multiple myeloma that has relapsed, potentially achieving undetectable cancer levels.
What could go wrong
This is an early-phase trial (Phase Ib/II) with a small number of participants, so results may not apply broadly. The new combination may cause side effects or not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.